← Eichor
Study identifier: NCT04672525 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Rifabutin Versus Rifampicin for Treatment of Staphylococcal PJI Treated With DAIR

Condition: Prosthetic Infection  ·  Sponsor: Tourcoing Hospital

PhasePhase 3
Planned participants436
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Rifampicin, is key in the treatment of staphylococcal PJIs. Rifabutin has a better profile of tolerance than rifampicin regarding the risk of interaction with concomitant medications and liver disorders. The hypothesis is that rifabutin may be an alternative antibiotic option as efficient as rifampicin for the treatment of staphylococcal PJIs, with a better safety profile. The investigator aim to demonstrate the non-inferiority of rifabutin as compared with rifampicin prescribed in combination treatment for PJIs.

This description comes directly from the study's public registry record.

Talk to the study team

Eric SENNEVILLE, MD PhD  ·  0320694949  ·  esenneville@ch-tourcoing.fr

Solange TREHOUX  ·  0320694280  ·  strehoux@ch-tourcoing.fr

Always discuss trial participation with your own doctor first.

Locations (30)

CHU Amiens PicardieAmiens, FranceNot Yet Recruiting
CHU AngersAngers, FranceNot Yet Recruiting
CHU BesançonBesançon, FranceRecruiting
CH de BéthuneBéthune, FranceNot Yet Recruiting
CHU BordeauxBordeaux, FranceNot Yet Recruiting
APHP Hôpital Ambroise ParéBoulogne-Billancourt, FranceNot Yet Recruiting
CHRU BrestBrest, FranceRecruiting
CHU CaenCaen, FranceRecruiting
CH Alpes LemanContamine-sur-Arve, FranceNot Yet Recruiting
CHU Dijon BourgogneDijon, FranceNot Yet Recruiting
CHU Grenoble AlpesGrenoble, FranceNot Yet Recruiting
CHRU LilleLille, FranceRecruiting

+ 18 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04672525